1-7 of 7
Eloise Scarano
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Outcomes of Venetoclax Retreatment after MRD-Guided Venetoclax +/- Ibrutinib: Results of the Improve Study

Elisa Albi, Lydia Scarfo, Silvia Heltai, Eloise Scarano, Luana Schiattone, Lucia Farina, Riccardo Moia, Marina Deodato, Andrea Ferrario, Marina Motta, Alessandro Noto, Rosaria Sancetta, Marta Coscia, Paolo Rivela, Luca Laurenti, Marzia Varettoni, Eleonora Perotta, Antonella Capasso, Pamela Ranghetti, Francesca Martini, Emanuela Sant'Antonio, Catalina Combi, Maria Colia, Paolo Ghia
Journal: Blood
Blood (2023) 142 (Supplement 1): 6521.
https://doi.org/10.1182/blood-2023-174603
Published: 2023
Journal Articles

Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL

Clinical Trials & Observations
Lydia Scarfò, Silvia Heltai, Elisa Albi, Eloise Scarano, Luana Schiattone, Lucia Farina, Riccardo Moia, Marina Deodato, Andrea Ferrario, Marina Motta, Gianluigi Reda, Rosaria Sancetta, Marta Coscia, Paolo Rivela, Luca Laurenti, Marzia Varettoni, Eleonora Perotta, Antonella Capasso, Pamela Ranghetti, Maria Colia, Paolo Ghia
Journal: Blood
Blood (2022) 140 (22): 2348–2357.
https://doi.org/10.1182/blood.2022016901
Published: 2022
Includes: Supplemental data
Journal Articles

Minimal Residual Disease-Driven Treatment Intensification By Sequential Addition of Ibrutinib to Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of the Monotherapy and Combination Phases of the Improve Study

Lydia Scarfo, Silvia Heltai, Elisa Albi, Eloise Scarano, Luana Schiattone, Lucia Farina, Gianluca Gaidano, Marina Deodato, Andrea Ferrario, Marina Motta, Gianluigi Reda, MD, Rosaria Sancetta, MD, Marta Coscia, MD PhD, Marco Ladetto, MD, Luca Laurenti, MD, Marzia Varettoni, Eleonora Perotta, Antonella Capasso, Pamela Ranghetti, Maria Colia, Paolo Ghia, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–22.
https://doi.org/10.1182/blood-2020-136507
Published: 2020
Journal Articles

R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma

Clinical Trials & Observations
Andrés J. M. Ferreri, Teresa Calimeri, Gian Marco Conte, Dario Cattaneo, Federico Fallanca, Maurilio Ponzoni, Eloise Scarano, Flavio Curnis, Alessandro Nonis, Paolo Lopedote, Giovanni Citterio, Letterio S. Politi, Marco Foppoli, Stefania Girlanda, Marianna Sassone, Salvatore Perrone, Caterina Cecchetti, Fabio Ciceri, Claudio Bordignon, Angelo Corti, Nicoletta Anzalone
Journal: Blood
Blood (2019) 134 (3): 252–262.
https://doi.org/10.1182/blood.2019000633
Published: 2019
Includes: Supplemental data
Journal Articles

Ofatumumab Is Active and Safe in Patients with Relapsed/Refractory Splenic Marginal Zone Lymphoma (SMZL): Results from the Interim Analysis of an Italian Multicenter Phase 2 Study (MORE trial)

Lydia Scarfo, MD, Silvia Ferrari, Annamaria Maria Frustaci, Monica Tani, Samantha Pozzi, MD, Eloise Scarano, Maria Colia, Pamela Ranghetti, Maurilio Ponzoni, MD, Paola Ronchi, MD, Andres JM Ferreri, MD, Paolo Ghia, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4162.
https://doi.org/10.1182/blood-2018-99-113875
Published: 2018
Journal Articles

Multicenter Phase II Trial Addressing Lenalidomide Maintenance in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Efficacy and Safety Results after a Median Follow-up of Five Years

Andres JM Ferreri, MD, Marianna Sassone, MD, Francesco Zaja, MD, Alessandro Re, MD, Michele Spina, MD, Alice Di Rocco, Alberto Fabbri, MD, Piera Angelillo, MD, Caterina Stelitano, MD, Maurizio Frezzato, MD, Chiara Rusconi, Renato Zambello, MD, Annalisa Arcari, MD, Giovanni Bertoldero, MD, Daniela De Lorenzo, BD, Eloise Scarano, Stefano Volpetti, MD, Salvatore Perrone, MD, Teresa Calimeri, MDPhD, Caterina Cecchetti, MD, Fabio Ciceri, MD, Maurilio Ponzoni, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1688.
https://doi.org/10.1182/blood-2018-99-116060
Published: 2018
Journal Articles

R-CHOP Preceded By Engineered Tumor Necrosis Factor (TNF) in Patients with Relapsed or Refractory (r/r) Primary CNS Lymphoma (PCNSL): Results of Antitumor Activity, Safety and Blood-Brain Barrier (BBB) Permeabilization in the "Ingrid" Phase II Trial

Andres JM Ferreri, MD, Teresa Calimeri, MDPhD, Gian Marco Conte, MD, Dario Cattaneo, MD, Federico Fallanca, MD, Maurilio Ponzoni, MD, Eloise Scarano, Marianna Sassone, MD, Salvatore Perrone, MD, Caterina Cecchetti, MD, Paolo Lopedote, MD, Fiorella Ilariucci, Roberta Rudà, MD, Emanuele Angelucci, MD, Carlo Visco, Francesco Pisani, MD, Alberto Fabbri, MD, Luigi Petrucci, MD, Marco Bregni, MD, Dario Marino, MDPhD, Guido Gini, MD, Fabio Ciceri, MD, Angelo Corti, MD, Nicoletta Anzalone, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1687.
https://doi.org/10.1182/blood-2018-99-118507
Published: 2018